Dimerix Limited (ASX:DXB)

Market Cap	123.08M -60.2%
Revenue (ttm)	6.35M +13.7%
Net Income	-29.81M
EPS	-0.05
Shares Out	600.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	300,416
Open	0.2000
Previous Close	0.2100
Day's Range	0.2000 - 0.2100
52-Week Range	0.1570 - 0.6650
Beta	0.35
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 24, 2026

About Dimerix

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Nina Webster
• Employees: 15
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: DXB

Financial Performance

In fiscal year 2026, Dimerix's revenue was 6.35 million, an increase of 13.73% compared to the previous year's 5.59 million. Losses were -29.81 million, 125.0% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error